Monte Rosa Therapeutics, Inc.

Industry

  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Technologies
      • ADMET
      • Molecular Diversity
See more in Biomedtracker

Latest on Monte Rosa Therapeutics, Inc.

Scrip

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Degron Therapeutics, a Chinese specialist in molecular glue degraders (MGD), is looking beyond technology-based, compound screening collaborations with multinational big pharmas. MGDs, an emerging dru

Scrip

Genentech, Orionis Stick Together In Second Molecular Glue Deal

 
• By Alaric DeArment

Who: Roche’s Genentech/Orionis Biosciences What: The companies signed a second deal focused on molecular glue drugs in oncology. Why: The deal expands on an existing partnership between Orionis

Scrip

Lilly/Magnet Molecular Glue Alliance Aims For Induced Proximity

 
• By Joseph Haas

AbbVie, Biogen, Pfizer and Novartis have each signed collaborations with biotechs centered on molecular glue degradation in fields such as cancer, immunology and neurology in just the past five months

Scrip

Molecular Glue Degraders Get Stickier With AbbVie/Neomorph Deal

 
• By Alaric DeArment

Who : AbbVie and Neomorph What: The two companies have signed a collaboration and option-to-license deal to develop molecular glue degraders in oncology and immunology. Why: The deal brings togeth